There is compelling medical need for continual improvements in the treatment of patients experiencing an acute ischemic stroke (AIS). The standard-of-care therapy, intravenous tissue plasminogen activator (IV tPA), continues to be limited in its application and effectiveness for subjects who are ineligible for or refractory to IV thrombolytic therapy [1, 2] .
Hence, interventional approaches to the treatment of AIS have been utilized for many years in this field, and recently IA endovascular treatment was found to be as safe and effective a therapy as the standard-of-care therapy [3] [4] [5] . Following these trials, however, the superior effectiveness of endovascular treatment remains to be proven.
At a Covidien-sponsored symposium during the European Stroke Congress, the stroke experts listed above presented and discussed data underscoring the benefits of endovascular therapy in treating AIS and, particularly, the important role that the Solitaire TM FR and similar new devices play when performing this procedure to remove blood clots from large vessels in the brain.
'Shorter time from onset of symptoms to restoration of blood flow and degree of reperfusion were crucial elements necessary to achieve better outcomes for patients with endovascular treatment in the IMS III trial', said Andrew Demchuk, MD, Director of the Calgary Stroke Program and Associate Professor at the Department of Clinical Neurosciences and Radiology at the University of Calgary's Foothills Medical Centre. 'This bodes very well for new endovascular devices such as the Solitaire FR Revascularization device, where short procedure times and high rates of reperfusion have been seen in recent studies. There is a very bright future for endovascular devices in the acute treatment of stroke. It is absolutely essential we focus attention on reducing all delays in our health system structure to dramatically reduce the time between symptom onset and therapeutic intervention. ' Prof. Patrik Michel, MD, Secretary General of the ESO and Chief of the Stroke Center at Centre hospitalier universitaire vaudois in Lausanne, Switzerland, moderated the session and made the following comments. 'Recent innovations in mechanical thrombectomy technology have led to improved outcomes, compared to first-generation devices designed to remove large blood clots in acute stroke patients. Prompt treatment with intravenous and endovascular approaches seems to be of paramount importance. Modern clot retrieval devices open a window to potentially treat patients well after the 4.5-hour window for IV tPA, but this needs to be proven in future randomized trials. ' The symposium was aimed to highlight, to the audience, Covidien's commitment to finding the clinical evidence for mechanical thrombectomy in treating AIS. The expert panel included principal investigators from Covidien's currently enrolling randomized controlled trial, SWIFT Prime, as well as those from three other important randomized controlled trials investigating mechanical thrombectomy with the Solitaire FR device: ESCAPE, EXTEND-IA and REVASCAT.
SWIFT Prime Study

Prof. Jeff Saver, MD, Professor of Neurology at the David Geffen School of Medicine and
Director of the UCLA Stroke Center, University of California, Los Angeles, USA The SWIFT Prime study is designed as a global, multicenter, two-arm, prospective, randomized, open, blinded endpoint (PROBE) investigational device exemption study comparing neurological outcomes (defined by modified Rankin Scale, mRS) in patients with established penumbral mismatch who are treated with either standard AIS therapy alone or standard AIS therapy in combination with Solitaire FR mechanical thrombectomy intervention. The objective is to determine if subjects experiencing an AIS due to large vessel occlusion, treated with combined IV tPA and Solitaire FR mechanical thrombectomy within 6 h of symptom onset, have superior outcomes compared with subjects treated with IV tPA alone. The first patient was enrolled in the study in January 2013, with a maximum sample size of up to 800 patients across 60 centers worldwide.
Key features of SWIFT Prime: • Solitaire FR has been proven, from the SWIFT and STAR studies, to be a highly effective and safe device • Only proximal anterior circulation vessels are targeted • The evaluation of penumbral imaging will confirm there is brain to be saved • All eligible patients are randomized consecutively in high-volume experienced centers across the globe • Time criteria to minimize progression of the stroke deficit
STAR Study
Prof. Antony Davalos, MD, Head of the Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
The STAR study is the largest controlled, prospective, multicenter study on the use of a Stentriever (Solitaire FR) for anterior circulation AIS. A total of 202 patients were enrolled in the study, with first enrollment in October 2010 and final enrollment in May 2012. The median age of the population was 72 years, and 60.4% of the patients were female. The median NIHSS (National Institutes of Health Stroke Scale) score was 17. The final patient follow-up occurred in September 2012 and the data were completely independently monitored and core-laboratory reviewed.
This nonrandomized prospective study suggests that treatment with the Solitaire FR device in intracranial anterior circulation occlusions results in:
• low risk of clinically relevant procedural and device-related complications;
• high rates of revascularization (Thrombolysis in Cerebral Infarction score ≥ 2b) and good clinical outcomes (mRS score 0-2); • low mortality at 90 days.
EXTEND-IA Study
Bruce Campbell, MD, Neurologist and Research Fellow, Royal Melbourne Hospital, Australia
This study is investigator-initiated, has a phase II PROBE design, includes 100 patients and uses 1: 1 randomization. The aim of the study is to evaluate the hypothesis that patients with anterior circulation ischemic stroke, selected with 'dual target' vessel occlusion and CT or MRI mismatch within 4.5 h of onset, will have improved reperfusion and early neurological improvement when treated with IA clot retrieval (Solitaire FR device) after IV tPA, compared with IV tPA alone. The first patient was enrolled in the study in August 2012, with a total of 19 patients enrolled as at the date of the European Stroke Congress from a total of 8 currently enrolling sites.
This study is different to the IMS III trial in many ways: • Dual target imaging selection; recent DEFUSE 2 (Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2) study results have emphasized the critical importance of a 'target mismatch profile' (i.e. small core, large penumbra) in predicting a favorable clinical response to reperfusion in patients undergoing IA therapy • Pure Solitaire FR clot retrieval intervention (recent SWIFT study results have demonstrated a clear superiority of the Solitaire FR device over Merci ® )
• A 0-to 4.5-hour inclusion window (IMS III: IV tPA <3 h) • Full dose IV tPA in both arms (IMS III: 0.6 mg/kg pre-IA)
• No upper age limit (IMS III: age ≤ 82 years) Key features of EXTEND-IA: • Solitaire is the most effective device currently available • Dual target imaging selection ensures there is a vessel occlusion and likely salvageable tissue • Inclusion criteria are otherwise broad (any tPA patient, no age limit as long as fit and independent)
